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A B S T R A C T
The potential for postmortem redistribution of olanzapine was investigated in beagle dogs. Olanzapine
pamoate monohydrate was administered once every 14 days by intramuscular injection for 3 months to
fed male dogs (n = 15) at a dose of 20 mg/kg olanzapine (equivalent to 46 mg/kg olanzapine pamoate
monohydrate). Blood samples were collected after the ﬁfth (Day 57) and sixth (Day 71) doses to
determine olanzapine and N-oxide olanzapine concentrations. On Day 71 at 72 h postdose, dogs were
euthanized and placed on their backs without additional manipulation and held for postmortem blood,
urine, and tissue collection at room temperature for up to 168 h postdose (96 h after euthanasia).
Concentrations of olanzapine and N-oxide olanzapine were determined by liquid chromatography–mass
spectroscopy/mass spectroscopy (LC–MS/MS). Postmortem olanzapine concentrations in blood
increased up to seven-fold compared to the last quantiﬁed antemortem blood concentration.
Olanzapine concentrations in vein tissue samples (surrogates for peripheral blood) also increased,
whereas other tissue concentrations, such as myocardium, lung, liver, and kidney decreased over the
postmortem period. An increase in blood concentration of olanzapine after death was observed in all but
one animal, suggesting that postmortem redistribution may occur in dogs following biweekly
intramuscular administration of olanzapine pamoate monohydrate. The rise in olanzapine concentra-
tions in blood after death in this study may potentially be attributed to diffusion from multiple tissues to
blood and, to a lesser extent, reduction of the N-oxide olanzapine metabolite back to olanzapine.
However, the generalizability of these results to humans cannot be conﬁrmed by the present study.
 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Olanzapine pamoate (Zyprexa Relprevv; Zypadhera) is a salt-
based, long-acting formulation of the oral atypical antipsychotic
olanzapine (Zyprexa). Once olanzapine pamoate is administered by
deep gluteal intramuscular injection, the diluent is absorbed and the
remaining olanzapine pamoate crystals slowly dissolve in the
muscle tissue until olanzapine is released via hydrolysis of the salt
for absorption into the bloodstream [1]. The slow intramuscular
release of this poorly soluble salt produces an extended release of
olanzapine for up to a month, with therapeutic olanzapine plasma
concentrations in the same range as the oral formulation [2–4].
Although the therapeutic plasma concentrations of oral
olanzapine have been well characterized, postmortem olanzapine
concentrations have not been well studied, and are potentially
subject to a wide variety of factors including the time course in* Corresponding author. Tel.: +1 317 276 9251; fax: +1 317 433 6432.
E-mail address: johnson_jason_t@lilly.com (J.T. Johnson).
http://dx.doi.org/10.1016/j.forsciint.2015.09.022
0379-0738/ 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access 
nd/4.0/).which samples are collected after death, how samples are collected
and stored, analytical methods used to analyze samples, and a
phenomenon known as postmortem redistribution [5,6]. Postmor-
tem redistribution refers to the movement of absorbed drugs from
areas within the body to different areas, such as from liver tissue
into the bloodstream or absorption of the unabsorbed drug from
body cavities after death, and the cessation of blood ﬂow [7,8].
Postmortem redistribution has been associated with drugs that
have a large volume of distribution (greater than 3–4 L/kg) and a
high degree of lipophilicity [9]. Postmortem concentrations of drugs
may increase substantially (of the order of 5- to 10-fold) compared to
antemortem concentrations [5,6,10] due to postmortem redistribu-
tion. For example, clozapine, an antipsychotic similar in structure to
olanzapine with a large volume of distribution, and its N-desmethyl
metabolite norclozapine have shown mean postmortem increases in
blood concentrations (presumed femoral) of 480 and 360%,
respectively in patients who are not thought to have died from an
overdose of clozapine [5].
Olanzapine is a lipophilic molecule that has an apparent large
volume of distribution (22 L/kg) [11]. Therefore, it would bearticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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death due to postmortem redistribution. In a review of case studies
(n = 273), where femoral blood samples were collected at
admission to the mortuary and at various times during autopsy
from deceased patients who had consumed oral olanzapine, 95
patients with olanzapine present in the blood specimen at
admission had a mean concentration increase of 112% over the
postmortem interval (the time elapsed since death) of 9 days
(range of 17–234%) leading the authors to conclude that
olanzapine is highly susceptible to postmortem redistribution
[6]. Further, larger postmortem increases may have occurred, but
could have been lost due to potential degradation in blood and
during sample preparation procedures [12].
Drug concentrations in samples taken postmortem are some-
times used to aid an investigator in determining if a speciﬁc drug
could have been involved in a death. However, postmortem
redistribution of a drug can make it difﬁcult to assess the
concentration of that drug in the antemortem phase [13,14].
The time from which a body is discovered after death, state of
decomposition, and environmental factors can make sample
collection, and interpretation of analytical results difﬁcult [15].
Additionally, some atypical antipsychotics, including olanzapine,
may be unstable in blood unless precautions are taken, such as
addition of antioxidants to reduce degradation [16,17].
Several studies have been conducted in animals to investigate
the potential for postmortem redistribution of drugs [9,18,19]. The
aim of the study described here was to investigate the postmortem
concentrations and possible postmortem redistribution of olanza-
pine in dogs following intramuscular administration of olanzapine
pamoate at steady state. Sample collection and processing, as well
as bioanalytical methodology, were carefully developed and
validated to address potential stability issues and provide a
reliable dataset. The overall design of the dog study was intended
to mimic the real life forensic situation in which patients may be
found deceased at room temperature from hours to days after
death and a subsequent autopsy is performed. To our knowledge,
this is the ﬁrst study to evaluate postmortem drug concentrations
for a long-acting depot drug formulation.
2. Materials
Olanzapine reference standard was obtained from the United
States Pharmacopeial Convention (USP) (Rockville, Maryland).
Reference standards for olanzapine N-oxide, olanzapine-d3, and
olanzapine-d3 N-oxide were obtained from Toronto Research
Chemicals (North Yo Ontario, Canada). Olanzapine pamoate
monohydrate was supplied by Eli Lilly and Company (Indianapolis,
IN) for the animal study. All other reagents and solvents were of
analytical grade and were obtained commercially.
3. Animal Experiment
This study was compliant with all applicable sections of the
Guide for the Care and Use of Laboratory Animals at Covance
Laboratories located in Greenﬁeld, IN. The procedures used in this
study are designed to avoid or minimize discomfort, distress, and
pain to animals. Male beagle dogs (Covance Research Products,
n = 15) with body weights ranging from 9.5 to 15 kg and age
ranging from 1.5 to 2 years old were individually housed.
Environmental conditions consisted of a temperature between
64 and 84 8F, a humidity range between 30 to 70%, and a
photoperiod of 12 h light, 12 h dark (unless interrupted for study-
related activities). The dogs were given water ad libitum and fed
daily with Harlan Teklab Global Dog Diet 2021, and food
consumption was evaluated by visual estimation of the food
remaining once daily. Clinical observations were assessed daily inthe morning and in the afternoon on nondosing days, and daily
before dosing, approximately 1 h after dosing, and in the afternoon
on the days of dosing. Body weights were measured prior to dosing
on each dosing day.
Olanzapine pamoate monohydrate (OPM) was administered
once every 14 days by intramuscular injection for 3 months at a
dose of 20 mg/kg olanzapine (equivalent to 46 mg/kg olanzapine
pamoate monohydrate). OPM was suspended in a vehicle
consisting of carboxymethylcellulose, mannitol, and polysorbate
80 in sterile water for injection at a concentration of 150 mg
olanzapine per mL. The test article was injected into the biceps
femoris muscle, alternating hind legs at each injection, at a dose
volume of 0.133 mL/kg. The dose of 20 mg/kg was the highest dose
that could be administered based on the formulation constraints
and the injection volume that could be delivered. Following the
ﬁfth dose of OPM (Day 57), blood samples were collected from the
jugular vein at predose, 4, 24, 48, 73, 84, 96, 120, and 168 h
postdose. After the sixth dose of OPM (Day 71), blood samples were
collected from the jugular vein at predose, 4, 24, and 48 h postdose.
Additionally, urine samples were collected from the cage pans after
the sixth dose from 0–24, 24–48, and 48–72 h postdose. At 72 h
after the sixth (ﬁnal) dose, dogs were induced with propofol, and
then euthanized with an injection of potassium chloride.
Dogs were placed on their dorsal side without additional
manipulation and held for postmortem blood, urine, and tissue
collections at room temperature. The euthanized dogs remained at
room temperature to mimic the real life forensic situation in which
patients may be found deceased at room temperature from hours
to days after death. Blood was collected from the left ventricle at 1,
12, 24, 48, and 96 h postmortem. These time points correspond to
the antemortem blood collection times 73, 84, 96, 120, and 168 h
postdose, respectively. Urine was collected via cystocentesis, and
tissue samples from liver (left lateral lobe), lung (right middle
lobe), myocardium (left side), large intestine (midsection of colon),
kidney (cross-section including medulla and cortex), and the last
injection site muscle were collected at the same postmortem time
points. Additionally, sections of hepatic vein, pulmonary vein, and
femoral vein were tied off and collected to evaluate peripheral
blood concentrations postmortem. All tissue and ﬂuid samples
were collected from three animals at each time point. All samples
except for injection site muscle tissue were analyzed for
olanzapine and N-oxide olanzapine concentrations; injection site
muscle was analyzed for olanzapine concentration only.
4. Sample Processing and Preparation
As described below, speciﬁc sample processing and preparation
steps were followed at the animal study site for all specimens
except urine samples in order to ensure olanzapine and olanzapine
N-oxide stability. Multiple solvents, buffers, and additives were
evaluated during the development of the sample processing and
preparation procedures with the primary objective of stabilizing
olanzapine and olanzapine N-oxide in the various matrices. In
general, mild antioxidants and acidic conditions yielded acceptable
storage and processing stability, while providing adequate analyte
recovery. Urine samples were analyzed within the long-term
stability (189 days at approximately 80 8C) established during
validation and thus, no special procedures were needed. Urine was
collected and frozen prior to analysis. Following the collection of
blood, olanzapine and olanzapine N-oxide were extracted by
adding 10.0 mL of acetonitrile to every 1 mL of blood immediately
after collection. The samples were vortexed and centrifuged for
10 min at 2–8 8C. The blood supernatant was collected and stored
frozen at approximately 80 8C.
Tissue samples from liver, lung, myocardium, large intestine,
kidney, and injection site muscle, as well as clamped sections of
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with sterile saline, and sliced into small pieces. Each tissue was
weighed (approximately 1 g) on an analytical balance and placed
in a polypropylene container. An equal weight of control (drug
free) liver tissue was added to the vein tissue samples to obtain the
tissue homogenate. A homogenization solution was added to each
tissue sample consisting of methanol and 0.22 M zinc sulfate
heptahydrate. The ratio of methanol: zinc sulfate was 80:20 (v,v)
for lung, myocardium, and vein tissue samples. The ratio was 50:50
(v,v) for liver, kidney, large intestine, and muscle from the injection
site. Per 1 g of sliced tissue sample, the following volumes of the
appropriate homogenization solution were added to the sliced
samples: vein samples—12.5 mL; liver, large intestine and kidney—
5 mL; myocardium—10 mL; lung—20 mL; muscle from injection
site—200 mL. Tissue homogenates were prepared using Hard Tissue
Omni Plastic Homogenizing Probes (Omni International) until no
resistance from the tissue was detected. Homogenates were vortexed
and centrifuged for 10 min at 2–8 8C. Supernatants were transferred
to clean polypropylene tubes and stored frozen at approximately
80 8C. To ensure stability of the analytes in the supernatant from
lung tissue, 10.0 mL of a 10% hydrochloric acid solution was added for
every 1 mL of supernatant prior to freezing. Tissue homogenates
were prepared at the time of excision to maintain stability.
5. Methods for Determining Concentrations of Olanzapine and
its N-Oxide
The methods for determining olanzapine and its N-oxide were
developed and validated at BASi, West Lafayette, IN. Sample
preparation involved thawing and then placing aliquots of each
supernatant and urine samples described above into individual
wells of 96-well plates and mixed with internal standards
(olanzapine–d3, olanzapine-N-oxide-d3). For most samples except
the supernatant from blood, acetonitrile was added to precipitate
any remaining protein. For the homogenate from the muscle
injection site, it was necessary to add a solution of 10% methanol and
90% water/ammonium formate/formic acid (100:0.025:0.1, v/v/v) to
precipitate remaining protein. Any remaining protein was pelleted
by centrifugation and aliquots of supernatants were transferred to
clean 96-well plates and reduced to dryness under nitrogen. Dried
residues were reconstituted with a mixture of methanol/mobile
phase A (10:90, v/v). The samples were then injected into an AB
SCIEX API 4000 LC–MS/MS system equipped with a Phenomenex
Synergi Polar RP column (150  2.0 mm, 4 mm) with a binary
gradient elution (Table 1) consisting of mobile phase A (water/
ammonium formate/formic acid, 100:0.025:0.1, v/v/v) and mobile
phase B (acetonitrile/water/formic acid, 90:10:0.1, v/v/v). AB SCIEXTable 1
HPLC/MS/MS binary gradient conditions used
for the analysis of samples for olanzapine and
N-oxide olanzapine.
Time (min) % B
0.00 13
0.50 13
2.10 20
3.50 50
3.60 100
4.90 100
5.00 13
6.00 end
Mobile phase A: H2O/ammonium formate/
formic acid, 100/0.025/0.1, v/v/v mobile
phase B: ACN/H2O/formic acid, 90/10/0.1, v/
v/v ﬂow rate: 0.6 mL/min from 0 to 4 min,
1.0 mL/min from 4.1 to 5.1 min, and 0.6 mL/
min at 5.2 to 6 min.Analyst software was used to capture the data, and Watson LIMS was
used to regress and quantitate the bioanalytical sample data.
Calibration curves and quality control samples were prepared from
each matrix under evaluation according to the same sample
preparation procedures described above. A weighted (1/x2, where
x is the concentration) least-squares regression analysis was used to
obtain a linear equation over the range of the calibration.
The assay was validated by fortifying tissue homogenates with
olanzapine and N-oxide olanzapine at three different concentra-
tions, at the lower limit of quantiﬁcation, the upper limit of
quantiﬁcation, and a midpoint concentration, and then analyzing
six replicates of each concentration on 3 separate days. The
calibration curve ranges, as well as the accuracy and precision for
each matrix obtained during the validation, are shown in Table 2.
The blood and urine concentration ranges were based on historical
upper and lower limits and the vein assay limits were equal to
blood, while the limits for highly perfused tissues were selected to
be 10-fold greater than blood. Since all tissues were diluted about
10-fold during homogenization, this yielded ﬁnal homogenate
concentrations in the approximate range of the whole blood assay,
therefore, only the vein assay required a more sensitive method.
The injection site muscle concentration range was meant to
provide an accurate estimate of the remaining olanzapine depot
dose. Additionally, the ability to analyze samples above the upper
limit of the calibration ranges was veriﬁed by preparing a sample of
each matrix at a very high concentration and conducting
appropriate dilutions to yield concentrations within the validated
ranges. Appropriate selectivity checks were conducted using blank
tissue homogenates. Evaluations of potential carryover, extraction
efﬁciency, as well as the evaluation of stability in the matrix and/or
supernatants were evaluated for each of the matrices.
Room temperature stability and approximately 80 8C frozen
storage stability of olanzapine and N-oxide olanzapine in urine and
in the tissue preparations, as well as an assessment of freeze/thaw
cycles (80 8C to room temperature), were determined. Further,
the reinjection reproducibility of samples left at room temperature
in the HPLC autosampler was also assessed. These assessments
were conducted in replicates of six at concentrations near the
lower and upper limits of quantiﬁcation, as well as at a very high
concentration, which required dilution. Results of the stability
assessments are shown in Table 3. All study samples were analyzed
within the known stability period.
During the study sample analyses, a set of quality control (QC)
samples were analyzed with each set of study samples and at least
two-thirds of the QC samples had to be within 15% in order for the
sample batch to be accepted. Descriptive statistics (mean, standard
deviation, and standard error of the mean) and exposure assessments
(area under the curve or AUC) for the blood and tissue concentration
data were calculated using Watson.
6. Results
To investigate the potential occurrence of postmortem redis-
tribution of olanzapine, blood proﬁles and concentrations of
olanzapine and N-oxide olanzapine from antemortem samples
were compared to those collected postmortem. Fig. 1 illustrates
the mean olanzapine blood concentration-versus-time proﬁles in
dogs after the ﬁfth (Day 57) and sixth (Day 71) doses of olanzapine
pamoate monohydrate. On Day 71, samples taken within 48 h of
injection represent antemortem concentrations, while those taken
at 73 h and beyond represent postmortem concentrations. Blood
area under the curve values from Day 57 and Day 71 are shown in
Fig. 2. The mean (SEM) partial AUC0–48 h value for olanzapine on
Day 57 was 899  202 ng h/mL. Following the sixth and ﬁnal dose on
Day 71, the mean (SEM) partial antemortem AUC0–48 h value was
780  80 ng h/mL, which is similar to the exposure observed on Day
Table 2
Validation data for the olanzapine and N-oxide olanzapine assay in various tissues.
Specimen Calibration curve range Accuracy (%RE) Precision (%RSD)
OLZ N-oxide OLZ N-oxide
Blood 1–100 ng/mL 3.2 to 5.6% 0.1 to 5.9% 2.7 to 6.2% 5.3 to 6.9%
Urine 1–100 ng/mL 10.0 to -0.7% 10.0 to 0.2% 2.8 to 5.6% 2.7 to 7.8%
Lung 10.5–1050 ng/g 7.4 to -1.6% 8.8 to -1.3% 2.7 to 7.3% 3.0 to 4.2%
Liver 9–900 ng/g 9.9 to -1.7% 8.5 to -4.4% 2.3 to 3.3% 2.9 to 3.3%
Myocardium 9.9–990 ng/g 9.6 to -1.1% 12.8 to -3.9% 1.5 to 4.5% 2.3 to 4.6%
Intestine 9–900 ng/g 9.8 to -3.0% 10.2 to -4.8% 2.0 to 4.1% 3.4 to 5.1%
Kidney 9–900 ng/g 9.1 to -2.1% 5.0 to 0.6% 3.1 to 4.0% 4.5 to 9.2%
Vein 1.09–109 ng/g 1.3 to 8.5% 0.5 to 3.7% 1.7 to 3.6% 2.3 to 9.3%
Injection Site Muscle 50.25–5025 mg/g 13 to 5.8% NA 3.2 to 9.4% NA
%RE = relative error; %RSD = relative standard deviation; NA = not applicable.
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antemortem exposure to olanzapine after the ﬁfth and sixth doses.
Following euthanasia, blood concentrations of olanzapine
increased over time (Fig. 1), with mean increases ranging from
1.7-fold at 1 h to seven-fold at 24 h in postmortem samples
compared to the last mean antemortem concentration (27.4 ng/
mL) on Day 71. Blood concentrations of olanzapine peaked at 24 h
after death and although more variability was observed in the
postmortem phase, concentrations remained elevated comparedTable 3
Stability data for olanzapine and N-oxide olanzapine in various specimens.
Specimen Room
temperature
(hours)
Freeze/
Thaw
(cycles)
Reinjectiona
(hours)
Frozen
at 80 8C
(days)
Blood 26 3 70 113
Urine 24 4 64 189
Lung 7 4 46 85
Liver 25 5 36 193
Myocardium 3 6 33 68
Intestine 24 4 44 168
Kidney 24 3 67 187
Vein 6 3 81 85
Injection Site Muscleb 24 3 53 97
a Refers to reinjection reproducibility of samples left at room temperature in the
HPLC autosampler.
b Olanzapine only, no assay for N-oxide olanzapine. Accuracy (% relative error)
and precision (% relative standard deviation) were all <15% except for room
temperature values for liver and intestine, which were <20%. N = 6 at three different
concentrations for each matrix; four different concentrations were evaluated for
reinjection reproducibility.
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also collected and served as surrogates to investigate the
postmortem concentrations of olanzapine in peripheral blood.
Blood in peripheral veins has been known to clot quickly after
death [17] unless provisions are taken such as injections of heparin
into the bloodstream prior to death [18]. In this experiment, the
study was conducted in an attempt to reﬂect a clinical postmortem
situation. No interventions were made to decrease the clotting
potential of blood after death. Therefore, sections of the vein
tissue including contents were tied off and removed from the
dogs for analysis. The concentrations of olanzapine in the vein
tissues are reﬂected by the postmortem AUC73–168 h values
shown in Fig. 4. Olanzapine postmortem exposure in blood
(AUC73–168 h), and femoral vein were comparable, while expo-
sures in the hepatic and pulmonary veins were 2.5 to 3.3 times
higher than that in blood, respectively. Thus, the olanzapine
exposure observed in the femoral vein representing the
peripheral blood demonstrated a similar postmortem increase
to blood. Very few vein tissue samples had quantiﬁable
concentrations of N-oxide olanzapine. Of those tissues with
quantiﬁable concentrations, the pulmonary vein produced the
majority of those ranging from 1.3 to 120 ng/g, whereas the
femoral and hepatic vein samples had negligible quantities of N-
oxide present. Therefore, N-oxide concentrations in vein tissue
postmortem  were not consistent and negligible compared to the
concentrations for olanzapine.
Postmortem organ tissue concentrations of olanzapine were
also assessed to determine if any speciﬁc tissues contributed to the
rise in postmortem olanzapine blood concentrations. The mean
 SEM postmortem olanzapine tissue concentrations, as well as
postmortem blood concentrations, are shown in Table 4. Fig. 5 shows
the ratio between olanzapine tissue concentrations and blood
olanzapine concentrations at 1, 12, and 24 h postmortem (Day 71
at 73, 84, and 96 h postdose, respectively). All tissues evaluated had
measureable concentrations of olanzapine, with the liver and lung
having the highest tissue-to-blood ratio at approximately 50:1 at 1 hTable 4
Mean  SEM olanzapine postmortem tissue concentrations (ng/g) in dogs.
Time (hr) Blooda Myocardium Intestines
(Hours) Mean  SEM Mean  SEM Mean  SE
73 46.6  13.6 595  194 475  319
84 157  103 695  395 1174  10
96 196  117 779  313 641  446
120 173  38.3 828  260 2323  21
168 50.6  19.5 248  32.3 149  56.4
a Blood is ng/mL, SEM = standard error of the mean, n = 3/tissue/time point.postmortem. In all tissues, the tissue-to-blood ratio decreased at the
next postmortem time point evaluated, 12 h postmortem, due in part
to rising blood concentration and decreases in tissue concentrations.
In general, this ratio was consistent throughout the remaining
postmortem period. Only a few selected tissue samples had
quantiﬁable concentrations of N-oxide olanzapine.
Urine samples were also collected after the ﬁnal dose during the
antemortem phase using a cage pan and during the postmortem
phase via cystocentesis. Concentrations of olanzapine in urine
increased throughout the collection intervals during the antemor-
tem phase. The 48–72 h antemortem collection produced a mean
concentration of 4383 ng/mL. After death, the urine concentrations
continued to increase, with peak concentrations occurring
between 84 and 96 h postdose (12–24 h postmortem, mean values
of 11,308 and 11,517 ng/mL, respectively). At 168 h after dosing,
urine concentrations had declined to 465 ng/mL. N-oxide olanza-
pine concentrations, which were roughly 20% of the olanzapine
concentrations, also increased during the urine collection period
(0–72 h postdose), and then declined to below the quantiﬁable
limit at 96 h postmortem (168 h postdose).
Muscle tissue from the last injection site was analyzed to
evaluate postmortem distribution from the depot dosing site. The
mean olanzapine concentration data were variable and ranged
from 176 to 860 mg/g. The large variance in olanzapine concen-
trations seen across the muscle tissue samples may be due to tissue
sampling inconsistency at the injection site. When administered,
olanzapine pamoate spreads throughout the muscle, thus,
sampling a core area around the injection site likely does not
reﬂect the total amount of olanzapine remaining in the muscle
tissue.
7. Discussion
In the current study, sample processing procedures and
bioanalytical methods were developed and validated to provide Kidney Liver Lung
M Mean  SEM Mean  SEM Mean  SEM
 700  222 2343  1244 2496  1365
70 579  345 2140  1531 798  540
 752  289 1850  1107 1343  922
67 1011  351 2155  489 1140  424
 543  238 558  53.6 226  39.2
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and its metabolite N-oxide olanzapine. Olanzapine is not stable in
blood samples for long periods of time, and N-oxide olanzapine
may be reduced back to olanzapine if precautions are not taken
with sample collection. To better ensure the stability of the
analytes in this study, samples were collected and processed by
protein precipitation and/or homogenization at the experimental
site rather than traditional practices, which would usually involve
freezing samples and conducting sample preparation after a
thawing cycle. Considering all of the sample collection, processing,
and storage precautions that were taken in the conduct of this
study, the data indicated that postmortem olanzapine concentra-
tions in blood were elevated up to seven-fold relative to
antemortem concentrations. Further, all but one dog had an
increase in blood olanzapine concentration postmortem compared
to their last antemortem blood olanzapine concentration. This
ﬁnding suggests that postmortem redistribution of olanzapine
may occur in a dog following intramuscular administration of
olanzapine pamoate monohydrate. The increases in blood and
peripheral vein tissue appeared to be related to redistribution of
olanzapine from a variety of tissues and, to a lesser extent, possible
reduction of the N-oxide olanzapine metabolite back to olanza-
pine. It is important to consider that the N-oxide metabolite could
potentially be reduced back to olanzapine during the postmortem
phase, which could contribute to the overall rise in olanzapine
concentration. Examples of the instability of N-oxide metabolites
have been reported [20]. Although precautions were taken to
stabilize both olanzapine and N-oxide olanzapine after collecting
samples, the stability of the analytes within the deceased dog are
not known. The reduction of N-oxide olanzapine to olanzapine is a
likely explanation for the decrease in exposure to the N-oxide
postmortem.
The data suggest that diffusion of olanzapine from liver and
lung tissues are likely the major contributors to the postmortem
blood olanzapine increases in this study. Further, this helps explain
the very high postmortem concentrations of olanzapine observed
in the hepatic and pulmonary vein tissue. Thus, olanzapine
concentrations in the femoral vein may be better suited to reﬂect
peripheral olanzapine concentrations. In fact, concentrations in the
femoral vein were consistent with postmortem redistribution,
with substantially elevated postmortem olanzapine concentra-
tions compared to antemortem blood olanzapine concentrations.
As shown in this study, the postmortem blood and femoral vein
olanzapine concentrations were similar; however concentrations
in hepatic and pulmonary veins were approximately three times
higher. Thus, depending on the site of blood collection during
autopsy, concentrations of the drug evaluated may vary due to the
antemortem tissue concentrations and the potential postmortem
redistribution of that particular drug.
In conclusion, results from the present study suggest that
postmortem redistribution of olanzapine may occur in dogs
injected with olanzapine pamoate, the long-acting formulation
of olanzapine. Although the generalizability of these results to
humans cannot be conﬁrmed by the present study, and the
magnitude of postmortem change in olanzapine blood concentra-
tion may vary between species, the results were consistent to
reports in the literature of postmortem redistribution in humans
who had consumed oral olanzapine [6]. Forensic assessments of
patients treated with olanzapine pamoate should be interpretedcarefully as postmortem olanzapine concentrations may not be
reﬂective of antemortem concentrations.
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